S&P 500
7,516.60
+0.45%
Dow Jones
52,923.60
+0.01%
Nasdaq 100
29,706.80
+1.19%
Russell 2000
3,007.21
+0.49%
FTSE 100
10,654.20
-0.33%
Nikkei 225
69,824.80
+2.22%
Corteva

Corteva (CTVA) Q3 2025 Earnings

Reported Nov 4, 2025 at 4:40 PM ET · SEC Source

Q3 25 EPS

$-0.23

BEAT +50.61%

Est. $-0.47

Q3 25 Revenue

$2.62B

BEAT +6.10%

Est. $2.47B

vs S&P Since Q3 25

+25.3%

BEATING MARKET

CTVA +35.2% vs S&P +9.9%

Market Reaction

Did CTVA Beat Earnings? Q3 2025 Results

Corteva turned in a notably strong third quarter, narrowing its seasonal loss far more than Wall Street had anticipated and raising its full-year outlook in the same breath. The agricultural sciences company posted a Q3 loss of $0.23 per share on an … Read more Corteva turned in a notably strong third quarter, narrowing its seasonal loss far more than Wall Street had anticipated and raising its full-year outlook in the same breath. The agricultural sciences company posted a Q3 loss of $0.23 per share on an adjusted basis, beating the consensus estimate of $0.47 by 50.61%, while revenue of $2.62 billion topped expectations by 6.10% and grew 12.6% year over year. The primary engine behind the outperformance was a 33% surge in Seed segment sales to $917 million, fueled by a 27% volume increase tied to early safrinha corn deliveries in Brazil, acre recovery in Argentina, and stronger EMEA demand. Crop Protection contributed as well, with sales rising 4% to $1.70 billion on gains in new products, herbicides, and biologicals. Management lifted full-year 2025 guidance to net sales of $17.70 to $17.90 billion and operating EPS of $3.25 to $3.35, while also unveiling plans to separate into two independent public companies by the second half of 2026, a move that drew fresh institutional interest in the stock.

Key Takeaways

  • • 27% volume increase in Seed driven by early safrinha deliveries in Brazil and corn acre recovery in Argentina
  • • 5% Crop Protection volume increase driven by demand for new products, herbicides, and biologicals
  • • Productivity savings and cost deflation across both segments
  • • Increased out-licensing income and demand for top technology in Seed
  • • Price-for-value strategy execution in North America and EMEA
24/7 Wall St

CTVA YoY Financials

Q3 2025 vs Q3 2024, source: SEC Filings

24/7 Wall St

CTVA Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q1 26
24/7 Wall St

CTVA Revenue by Geography

With YoY comparisons, source: SEC Filings

Q2 25 Q1 26

“We delivered a strong third quarter across the company, reinforcing our conviction that our two businesses will continue to thrive as independent public companies. In Crop Protection, demand for differentiated technology and productivity gains support margin expansion, while Seed continues to benefit from its strength in advanced genetics, growth in out-licensing and ongoing cost discipline.”

— Chuck Magro, Q3 2025 Earnings Press Release

Back to CTVA Stock Page